Tango Therapeutics【TNGX】銘柄情報

Tango Therapeutics Inc (TNGX) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

29.84

( 4.04% )

買値

29.38

売値

29.84

出来高

6,446,170

28.065 日の範囲 30.00

4.3216 52 週間の範囲 32.79

時価総額

4.316B

前日終値

28.68

始値

28.81

時刻

200

29.84

(formt)

最終取引時間

財務取引量

US$ 185,883,692

VWAP

28.8363

平均取引量 (3 か月)

US$ 3,041,284

発行済株式数

144,647,982

配当利回り

PER

-23.47

1 株当たり利益 (EPS)

-0.86

歳入

56.99M

純利益

-107.23M

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is ... Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.tangotx.com

本社

Boston, United States

設立

2026

Tango Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker TNGX. The last closing price for Tango Therapeutics was US$28.68. Over the last year, Tango Therapeutics shares have traded in a share price range of US$ 4.3216 to US$ 32.79.

Tango Therapeutics currently has 144,647,982 shares in issue. The market capitalisation of Tango Therapeutics is US$4.32 billion. Tango Therapeutics has a price to earnings ratio (PE ratio) of -23.47.

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 424B5 - Prospectus [Rule 424(b)(5)]

Tango Therapeutics Announces Proposed $500 Million Public Offering

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage...

Form 8-K - Current report

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat...

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	8.37	38.9846297159	21.47	32.79	19.4275	8826767	29.30737754	CS
4	6.08	25.5892255892	23.76	32.79	19.342	4614031	25.4084771	CS
12	11.16	59.7430406852	18.68	32.79	18.4601	3424434	23.93344845	CS
26	20.67	225.408942203	9.17	32.79	8.3	3267644	18.25780557	CS
52	25.28	554.385964912	4.56	32.79	4.3216	2941174	13.34058463	CS
156	26.52	798.795180723	3.32	32.79	1.03	1807524	9.98958213	CS
260	20.23	210.509885536	9.61	32.79	1.03	1209939	9.7774124	CS